← board
APLM
Apollomics Inc.distress 4/10 · elevated risk$18.60-1%today-49% from 52w high
Oncology 1
Lead: Solid Tumors · target EGFR
Revenue
pre-revenue
Liquidity
$3M
Runway
0.3 yrs
Shares 1y
0%
Price & events
-0.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.6%
1D
-3.1%
1W
-18.5%
1M
+37.9%
3M
-0.5%
6M
+186.2%
1Y
-9.3%
2Y
—
5Y
-98.1%
All
Overview
- Market Cap
- $40.85M
- Volume
- 15.50K
- 52 Week Range
- $3.93 – $36.65
- Total Shares
- 2.20M
- Float Shares
- 1.24M
- Short %
- 0.46%
- % Held by Insiders
- 47.10%
- % Held by Institutions
- 0.06%
- RVOL
- 0.57x
- Beta
- 1.44
Pipeline stages · 1 programs
APL-101 Oral CapsulesEGFR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-03-30 | Phase 2 | APL-101 Oral Capsules | Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping | 497 | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 2,196,052 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — EGFR
Recent news
- 2026-07-21Apollomics appoints Hung-Hsien Yen to board after two directors resign - Bitget
- 2026-07-21Apollomics Inc. (APLM) appoints Hung-Hsien Yen to board - Stock Titan
- 2026-07-17Apollomics Inc. (APLM) Plunges Over 21%: Key Support Levels Tested Amid Heavy Selling - IV Rank - dars.gov.et
- 2026-07-14Apollomics (Nasdaq: APLM) restores compliance with Nasdaq $35M MVLS rule - Stock Titan
- 2026-07-13Apollomics Regains Full Compliance with Nasdaq Listing Requirements - GlobeNewswire
- 2026-07-13Nasdaq restores Apollomics listing compliance after MVLS climbs back to $35M - Stock Titan
- 2026-06-30Apollomics Inc. (APLM) Plunges Over 10%, Testing Key Support at $18.14 - Dynamic Hedging - dars.gov.et
- 2026-06-24Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.